Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer
17 April 2024 - 11:03PM
Business Wire
- Sean will drive the Company through its next phase of growth
and bring its highly promising pipeline through clinical
development
- He brings more than 20 years of senior executive experience in
the life science industry across business development, operations,
and strategy
Domain Therapeutics a global clinical-stage biopharmaceutical
company developing innovative drug candidates in immuno-oncology
targeting G Protein-Coupled Receptors (GPCRs), today announces the
appointment of Sean A. MacDonald as its Chief Executive Officer
(CEO).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240417480644/en/
Sean Mc Donald, CEO Domain Therapeutics
(Photo: Business Wire)
Sean, formerly Executive Strategic Advisor and most recently
Chief Business Officer of Domain Therapeutics, has played a pivotal
role over the past year in defining, alongside Domain’s management
team, both corporate and clinical strategy. His efforts have been
instrumental in positioning the development stage assets of
Domain’s proprietary portfolio of GPCR-targeting immunotherapies.
Sean’s in-depth knowledge and experience within all aspects of
Domain’s operations, will be invaluable in driving the Company’s
next phase of growth, leading and executing the Series B
fundraising. As he steps into his new role as CEO, he will continue
to pave the way for Domain towards maturing into a global clinical
company. His leadership will be crucial in advancing and expanding
Domain’s innovative portfolio of pioneering anticancer
candidates.
Sean has a proven international track record of success in
strategy and business development in several executive positions in
the pharmaceutical industry (iOnctura, Cosmo Pharmaceuticals,
Corbin Therapeutics Inc, Pharmascience Inc.), leading and closing
multiple deals, including mergers and acquisitions, critical
investments, fundraising and licensing activities, whilst building
successful biotech companies in North America and Europe. In
addition, he currently serves as a Board Director at Edesa
Biotech.
Laurence Rulleau, Chair of the Board of Directors of Domain
Therapeutics, said: “Sean’s profound understanding of Domain
and strategic and operational expertise, executing deals at the
most senior levels of business development and planning, makes him
ideal to be at the operative helm of the Company as CEO. The
Board’s unanimous decision ensures Domain is in a solid position to
maximise its strong growth prospects. I am confident that this new
leadership will drive Domain’s evolution as a global cancer company
and move the Company forward towards even greater success to the
benefit of cancer patients and their families. Sean succeeds
Anthony Johnson, who I’d like to thank for his support of the
Company.
Sean A. MacDonald, Chief Executive Officer of Domain
Therapeutics, commented: “2024 is set to be a pivotal year for
the Company and I am honoured to have been given the opportunity to
lead and support the tremendous talent at Domain. Over the past
several months, I have witnessed first-hand the remarkable strength
of our team and the exceptional science we are developing. I look
forward to continuing to drive our programs forward through the
clinic and bring better and more effective treatment options to
cancer patients worldwide.”
About Domain Therapeutics :
www.domaintherapeutics.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417480644/en/
Press:
ICR Consilium DomainTherapeutics@consilium-comms.com Tel:
+44 (0)20 3709 5813